Pharmafile Logo
Pharmafocus logo
Advanced Search

Crohn’s disease

Showing 15 posts of 35 posts found.

Polpharma Biologics and Fresenius Kabi partner to develop treatment for ulcerative colitis and Crohn’s disease

August 5, 2025
Mergers and Acquisitions Corporate, Crohn’s disease, Fresenius Kabi, Gastrointestinal tract, Polpharma Biologics, ulcerative colitis

Polpharma Biologics has signed a global licensing agreement with Fresenius Kabi for the commercialisation of PB016, a proposed biosimilar to …

News

A challenge we can no longer ignore: meeting the needs of people with Crohn’s Disease in the UK

August 3, 2025
Research and Development Crohn’s disease, Immunology, Lilly UK, autoimmune disease, immunology

By Holly Thomas, Associate Vice-President Specialty Care at Lilly UK and Ireland Immunology care in the UK is at a …

Feature
bowel_cancer_screening

NICE recommends NHS use of mirikizumab for Crohn’s disease

July 11, 2025
Medical Communications, Research and Development Crohn’s disease, Gastrointestinal tract, Medicines and Healthcare products Regulatory Agency, NHS, National Institute for Health and Care Excellence (NICE), bowel disease, clinical trial

Eli Lilly (Lilly) has announced that the National Institute for Health and Care Excellence (NICE) has recommended mirikizumab (omvoh) for …

News
money_pills_2

EVerZom receives €3m funding from French government to industrialise exosome technology

June 18, 2025
Research and Development BpiFfrance, Corporate, Crohn’s disease, EVerZom, France 2030, French government, age-related disorders, exosome therapy, neurodegenerative disease

EVerZom, a French biopharma company focused on exosome-based therapies, has announced it has received €3m in funding as part of …

News
clinical_trials_2

NICE recommends mirikizumab (Omvoh ▼) for previously treated moderately to severely active Crohn’s disease 1

May 30, 2025
Research and Development Crohn’s disease, Eli Lilly and Company, Gastrointestinal tract, Medicines and Healthcare products Regulatory Agency (MHRA)(, NHS England and Wales, National Institute for Health and Care Excellence (NICE), Omvoh, inflammatory bowel disease (IBD), mirikizumab

In the Phase 3 VIVID-1 trial, patients treated with mirikizumab experienced significant improvement in clinical remission and endoscopic response at …

News
Press release
bowel_cancer_screening

European Commission approves Johnson & Johnson’s Crohn’s disease therapy

May 12, 2025
Market Access, Research and Development, Sales and Marketing Crohn’s disease, European Commission, Gastrointestinal tract, Johnson & Johnson, guselkumab, marketing authorisation

The European Commission (EC) has granted Marketing Authorisation (MA) to Johnson & Johnson’s Tremfya (guselkumab) for the treatment of moderately …

News

Eli Lilly shares positive results from phase 3 VIVID-1 trial of Crohn’s disease treatment

May 22, 2024
Medical Communications Crohn’s disease, Eli Lilly, Endocrinology, clinical trial, mirikizumab

Eli Lilly has announced results from its pivotal phase 3 VIVID-1 study, which assessed patients with moderately to severely active …

News
louis-reed-pwckf7l4-no-unsplash_5

Sanofi and Teva partner for development of inflammatory bowel disease treatment

October 4, 2023
Medical Communications Crohn’s disease, Gastrointestinal tract, Sanofi, Teva, bowel disease, ulcerative colitis

Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation of TEV’574, a treatment for …

News

Research shows neonatal stem cells could be used as treatment for Crohn’s disease

July 31, 2023
Research and Development Crohn’s disease, Gastrointestinal tract, Stem cells, gastrointestinal

Recent studies from the Ann & Robert H Lurie Children’s Hospital in Chicago have discovered that human neonatal cardiac-derived mesenchymal …

News
takeda_usa_pharmaceuticals_u

Takeda’s subcutaneous Entyvio approved in Europe for maintenance of moderate to severe Crohn’s and ulcerative colitis

May 11, 2020
Sales and Marketing Crohn’s disease, Entyvio, Takeda, crohn's disease, ulcerative colitis

The European Commission has awarded marketing approval to Takeda’s subcutaneous formulation of its gut-selective biologic therapy Entyvio (vedolizumab) as a …

News
janssen_latest_logo_on_sign_closer

Janssen shows off Phase 3b interim data for Stelara in Crohn’s disease

February 18, 2020
Manufacturing and Production, Research and Development Crohn’s disease, Janssen, Stelara, crohn's disease, pharma

Janssen has revealed new interim Phase 3b data from a study investigating the efficacy of Stelara (ustekinumab) in the treatment …

News
entrance_takeda_i020_v1

Strong Phase 3 data for Takeda’s subcutaneous Entyvio in moderate to severe Crohn’s disease

February 17, 2020
Research and Development, Sales and Marketing Crohn’s disease, Entyvio, Takeda, crohn's disease, pharma

Takeda has shared positive new Phase 3 data on a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab) as a …

News
takeda_usa_pharmaceuticals_u

Takeda’s subcutaneous formulation of Entyvio smashes primary endpoint in Crohn’s disease

July 23, 2019
Manufacturing and Production, Research and Development Crohn’s disease, Entyvio, Takeda, crohn's disease, pharma

Takeda has unveiled new Phase 3 data for a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab), showing that the …

News
takeda_global_hq

Takeda scores Japanese Entyvio approval in Crohn’s disease

May 22, 2019
Research and Development, Sales and Marketing Crohn’s disease, Entyvio, Japan, crohn's disease, pharma

Takeda has announced that Japan’s drug regulator, the Ministry of Health, Labour and Welfare (MHLW), has approved Entyvio (vedolizumab) in …

News

Stem cells could ‘reset’ immune system in Crohn’s disease patients

August 8, 2018
Research and Development Crohn’s disease, Stem cells, crohn's disease, trials

A clinical trial led by researchers at Queen Mary University, London is looking into ways in which patients with Crohn’s …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026